Chris Howie International Ltd (CHIL)
formed by Director, Chris Howie in 2011
Chris Howie has held several other full-time life sciences industry positions with:
Eli Lilly, AstraZeneca, Pfizer, Bioquell, BD, Genus Pharma, Nordic medical supplies and Gruenthal Group
30 years commercial healthcare experience with a proven track record in life science/healthcare business development and sales success: from start ups to global leaders in pharmaceuticals, medical technology and diagnostics. (AZ, Eli Lilly, Pfizer, BD).
Extensive experience working within the UKs NHS and in depth understanding, knowledge and experience of the successful business launches in the UK and the EU markets.
Excellent Start-up record.
Formed CHIL in 2011
2011 - present
Supporting UK and European Life Sciences SMEs and Startups successfully develop their businesses and support their overall growth ideally moving towards M & A activity.
Non Executive Director, MediShout
2020 - present
Investor, support with Commercial contract landings.
Introduction to the USA, European and Israeli markets.
Using MediShout to Support the fight against COVID-19.
Non Executive Director, Batel
Feb 2020 - present
Supporting the formation of Batel within the UK, locating offices and Labs. Negotiating with MHRA to confirm clinical trial programme for approval. Find and support product manufacturing and product storage facilities. Develop key opinion network within the UK for product launch.
European Life Science Specialist, Department for International Trade, London
Feb 2015 - Mar 2020
Supporting the UK government Life Sciences offering promoting the UK as the Number 1 Life Sciences hub.
Supporting a pipeline of life science Start-ups and SMEs (Pharma, Med tech, Digital) investing in the UK. Supporting their landing and financing into the U.K. and the NHS/private healthcare arena.
Work with the largest Clinical Entrepreneur Programme in the world as a business mentor. Investing and advising life science start-ups.
Head of Sales and Marketing, Hutman Diagnostics, Basel Switzerland
Mar 2013 - Jun 2015
Launch of Portfolio of Multiplex PCR testing to EMEA primarily UK Germany and Switzerland for an in vitro diagnostics product development and portfolio management company, which specialises in DNA based applications.
Engagement with key European and EMEA microbiology professors and consultants in the development and direct market access of innovative in vitro diagnostics kits for infectious diseases.
All Hutman products employ the same technology platform: universal PCR, species-specific microarray hybridisation and software-based readout. Sample preparation methods vary to guarantee optimal DNA extraction and sensitivity.
Business Development Director, (contracted to Lightintegra Technology Inc. Vancouver Canada)
Aug 2011 - Mar 2013
Launched ThromboLUX in EU markets– a new dynamic light scattering technology monitoring the overall quality of platelet for transfusions.
Launching a new platelet quality monitoring technology within Europe and the Middle East.
Worked to open up the European, Australian, Asian and Middle East Platelet Transfusion. Market for new opportunities.
Developing KOL and producing Overall Sales Pipeline.
Ongoing Market Access development and Health Economic Modelling within the Blood Platelet Therapy area.
Direct Account Management with Red Cross Blood Centres throughout Europe.
Hospital Economic Liaison Manager, Market Access, Grunenthal UK
May 2011 - Aug 2011
Responsible for securing the formulary approval of Palexia approval with the Imperial Trust London.
General Manager, Nordic Medical Supplies
Jun 2010 - Apr 2011
Responsible for launching NMS into the UK.
Apr 2007 - Apr 2011
Responsible for driving the double digit sales line growth for Apomorphine in Parkinson Disease.